ATE268597T1 - Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen - Google Patents

Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen

Info

Publication number
ATE268597T1
ATE268597T1 AT00903441T AT00903441T ATE268597T1 AT E268597 T1 ATE268597 T1 AT E268597T1 AT 00903441 T AT00903441 T AT 00903441T AT 00903441 T AT00903441 T AT 00903441T AT E268597 T1 ATE268597 T1 AT E268597T1
Authority
AT
Austria
Prior art keywords
compositions
methods
increase
blood cells
white blood
Prior art date
Application number
AT00903441T
Other languages
English (en)
Inventor
Ronald Trevor Macfarland
Andrew W Miller
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of ATE268597T1 publication Critical patent/ATE268597T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT00903441T 1999-02-02 2000-02-02 Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen ATE268597T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02
PCT/CA2000/000104 WO2000045814A1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count

Publications (1)

Publication Number Publication Date
ATE268597T1 true ATE268597T1 (de) 2004-06-15

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903441T ATE268597T1 (de) 1999-02-02 2000-02-02 Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen

Country Status (24)

Country Link
US (2) US6365583B1 (de)
EP (1) EP1148875B1 (de)
JP (2) JP4968868B2 (de)
KR (1) KR100643553B1 (de)
CN (1) CN1310642C (de)
AP (1) AP1497A (de)
AT (1) ATE268597T1 (de)
AU (2) AU772979B2 (de)
BR (1) BR0007924A (de)
CA (1) CA2361587C (de)
CZ (1) CZ20012698A3 (de)
DE (1) DE60011391T2 (de)
DK (1) DK1148875T3 (de)
ES (1) ES2222174T3 (de)
HK (1) HK1038319B (de)
HU (1) HUP0200100A3 (de)
IL (1) IL144400A (de)
MX (1) MXPA01007801A (de)
NO (1) NO20013770L (de)
NZ (1) NZ513602A (de)
PT (1) PT1148875E (de)
SI (1) SI1148875T1 (de)
TR (1) TR200102239T2 (de)
WO (1) WO2000045814A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2001044229A1 (en) * 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
EP1752455B1 (de) * 2000-09-15 2010-11-10 Anormed Inc. Chemokin Rezeptor bindende heterozyklische Verbindungen
HUP0301094A2 (hu) * 2000-09-15 2003-09-29 Anormed Inc. Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE60136476D1 (de) 2000-09-29 2008-12-18 Anormed Inc -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
KR100996378B1 (ko) * 2001-07-31 2010-11-25 아노르메드 인코포레이티드 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
HUP0600777A2 (en) 2001-09-12 2007-01-29 Anormed Inc Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
HUP0402458A2 (hu) * 2001-12-21 2005-07-28 Anormed Inc. Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
US7291631B2 (en) * 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
ES2393188T3 (es) * 2003-04-22 2012-12-19 Genzyme Corporation Compuestos heterocíclicos que se unen a los receptores de quimiocina y presentan eficacia mejorada
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
CA2548393A1 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
JP2008543858A (ja) * 2005-06-15 2008-12-04 ジェンザイム・コーポレーション ケモカインレセプター結合化合物
CA2619881A1 (en) * 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
ES2497092T3 (es) * 2006-02-24 2014-09-22 Genzyme Corporation Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
CN101500595A (zh) * 2006-08-07 2009-08-05 健赞股份有限公司 组合治疗
EP2759302A3 (de) 2006-12-21 2014-11-05 Biokine Therapeutics LTD. 4F-benzoyl-TN14003 kombiniert mit Rituximab für die Verwendung in der Behandlung eines Tumors
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112013029482A2 (pt) * 2011-05-16 2016-08-09 Genzyme Corp utilização de antagonistas cxr4
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
EP3322431A2 (de) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
EP3389634B1 (de) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Verfahren zur behandlung von krebs
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN109187337A (zh) * 2018-09-10 2019-01-11 南京工业职业技术学院 一种筛选强韧性FeAl晶界的方法
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
JP2002529502A (ja) * 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法

Also Published As

Publication number Publication date
AU772979B2 (en) 2004-05-13
JP2002536329A (ja) 2002-10-29
HUP0200100A3 (en) 2004-07-28
KR100643553B1 (ko) 2006-11-10
US20020058653A1 (en) 2002-05-16
MXPA01007801A (es) 2003-06-04
DE60011391T2 (de) 2005-07-14
CN1310642C (zh) 2007-04-18
JP2011088937A (ja) 2011-05-06
CA2361587C (en) 2010-04-20
AU2527800A (en) 2000-08-25
HK1038319A1 (en) 2002-03-15
DE60011391D1 (de) 2004-07-15
ES2222174T3 (es) 2005-02-01
HUP0200100A2 (hu) 2002-05-29
SI1148875T1 (en) 2004-12-31
DK1148875T3 (da) 2004-10-18
EP1148875A1 (de) 2001-10-31
KR20010101896A (ko) 2001-11-15
HK1038319B (en) 2005-03-18
IL144400A0 (en) 2002-05-23
US6365583B1 (en) 2002-04-02
CZ20012698A3 (cs) 2002-03-13
AP1497A (en) 2005-11-20
BR0007924A (pt) 2001-11-06
US6670354B2 (en) 2003-12-30
NO20013770D0 (no) 2001-08-01
WO2000045814A1 (en) 2000-08-10
PT1148875E (pt) 2004-10-29
JP4968868B2 (ja) 2012-07-04
CN1338933A (zh) 2002-03-06
TR200102239T2 (tr) 2002-01-21
NO20013770L (no) 2001-09-27
NZ513602A (en) 2003-10-31
IL144400A (en) 2010-05-17
EP1148875B1 (de) 2004-06-09
AU2004203847B2 (en) 2007-03-22
AP2001002221A0 (en) 2001-09-30
CA2361587A1 (en) 2000-08-10
AU2004203847A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
ATE268597T1 (de) Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen
DE60008157D1 (de) Verfahren zur Herstellung von härtbaren Zusammensetzungen und Zusammensetzungen daraus
DE60003250D1 (de) Reinigungszusammensetzungen und Verfahren zur Reinigung
EP1227821A4 (de) Therapeutische zusammensetzungen und verfahren zur verwendung davon
DE60042883D1 (de) Zusammensetzungen und verfahren zur veränderung der gentranskription
DE60128168D1 (de) Tablette und Verfahren zur Herstellung derselben
DE69900449D1 (de) Verfahren zur Herstellung von Glycerincarbonate
DE69903515D1 (de) Zusammensetzung zur herstellung von temporären zahnkronen und haltebrücken
DE60002505D1 (de) Lithium kobaltoxide und verfahren zur herstellung
DE69937171D1 (de) Verfahren zur Herstellung von arylierten Poly-alpha-Olefinen
DE69918842D1 (de) Desinfektionszusammensetzungen und verfahren
DE60038663D1 (de) Thyristoren und verfahren zur herstellung
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE60022818D1 (de) Tastenfolie und Verfahren zur Herstellung derselben
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
DE69914175D1 (de) Thermoplastische Zusammensetzung und Verfahren zur Herstellung derselben
DE69936544D1 (de) Egioreguläres copolymer und verfahren zur herstellung
DE60033941D1 (de) Neuartiges verfahren zur herstellung von l-epi-2-inosose und neuartiges verfahren zur herstellung von epi-inositol
DE69935509D1 (de) Verfahren zur herstellung von durchscheinenden zahnersätzen
DE69806832D1 (de) Verfahren zur Herstellung von Octaphenylcyclotetrasiloxan und Sym-Tetramethyltetraphenylcyclotetrasiloxan
EP1075184A4 (de) Zusammensetzungen und verfahren zur aktiven impfung
EP1073333A4 (de) S-rabeprazol enthaltende zusammensetzungen und verfahren
DE60002784D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE60008312D1 (de) Fluoreszentes Material und Verfahren zur Herstellung desselben
DE60117876D1 (de) Verfahren und esterderivate zur herstellung von cephalosphorinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1148875

Country of ref document: EP

EENE Nomination of inventor
REN Ceased due to non-payment of the annual fee